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2796pigs (8). The caval-aortic tract
can be closed using nitinol
occluder devices, and counterin-
tuitively, is well tolerated even
when not repaired. We describe
the ﬁrst use of this technique in
humans undergoing TAVR who
were believed not to have other
access options.Methods
Case selection. Patients were
selected from the high-riskFigure 1 Schematic Depiction of Caval-Aortic Access
(A) A catheter directs a transfemoral vein guidewire from the inferior vena cava
towards a snare target positioned in the adjoining abdominal aorta. (B) A catheter
is advanced over the guidewire into the aorta and used to introduce a more rigid
guidewire. (C) The valve introducer sheath is advanced from the vena cava into the
aorta. (D) After completion of transcatheter aortic valve replacement, the aorto-
caval access tract is closed with a nitinol occluder.structural heart disease program at Henry Ford Hospital,
Detroit, Michigan. All had severe symptomatic aortic
valvular heart disease deemed to be high or prohibitive
surgical risk. The multidisciplinary team of surgeons, car-
diologists, and anesthesiologists concurred these patients
would likely beneﬁt from TAVR, but were not suitable for
femoral arterial or transapical delivery of the transcatheter
valve. For the ﬁrst 11 patients, transaortic surgical access was
not an option at our institution; subsequent patients were
also deemed ineligible for transaortic delivery (severe lung
disease and morbid obesity, n ¼ 2; porcelain aorta, n ¼ 2;
frailty and poor rehabilitation potential, n ¼ 3; previous
chest irradiation, n ¼ 1). All underwent TAVR under
general anesthesia using Sapien transcatheter heart valves
(Edwards Lifesciences, Irvine, California). Patients con-
sented to clinical treatment despite explicitly high risk. The
institutional review board of Henry Ford Hospital approved
this analysis and report.
Caval-aortic access technique during TAVR. Contrast-
enhanced computed tomography (CT) was used to select a
caval-aortic crossing trajectory with the least-calciﬁed aortic
wall and no interposed structures, to determine suitable
angiographic projection angles and ﬂuoroscopic landmarks
in relation to lumbar vertebrae. After simultaneous aortog-
raphy and venography, and heparin administration, a
gooseneck snare was positioned to “receive” a crossing
guidewire in orthogonal ﬂuoroscopic projections (Fig. 1).
A coaxial crossing system (Fig. 2) consisting of a stiff
0.014-inch guidewire (Asahi ConﬁanzaPro12, Abbott
Vascular, Santa Clara, California) inside a 0.035-inch wire
convertor (Piggyback, Vascular Solutions, Minneapolis,
Minnesota) inside a support catheter (Navicross, Terumo,
Somerset, New Jersey) was inserted into a guiding catheter
(RDC or RDC1) selected on the basis of caval diameter.
The crossing system was directed from the cava towards the
aortic snare, which served as a target. The proximal guide-
wire end was connected to a unipolar electrosurgery pencil
(Valleylab, Covidien, Mansﬁeld, Massachusetts) using for-
ceps, and the patient was connected to a ground pad. The
distal crossing tip of the guidewire was extended 2 to 5 mm
beyond the wire convertor and energized in “cutting mode”
at 50 to 70 W to vaporize target tissue during 2- to 3-sbursts. After the ﬁrst 9 patients, we amputated the distal
1 cm of the guidewire to ease crossing. The snare conﬁrmed
intraluminal wire position and provided countertraction to
advance the crossing system into the aorta (Online Video 1).
The crossing devices were replaced with a rigid guidewire
(0.035-inch Lunderquist, Cook, Bloomington, Indiana).
The appropriate sized 35-cm-long Edwards TAVR intro-
ducer sheath (Retroﬂex 3 models 9120S23 [22-F] or
9120S26 [24-F]) was delivered from the femoral vein into
the IVC, through the caval-aortic tract and into the
abdominal aorta in a single step without progressive dilation.
Aortography was performed immediately after sheath
placement to assure hemostasis. TAVR was then performed
in the usual manner.
After TAVR, the tract was closed with a nitinol occluder
device marketed to close ductus arteriosus (Amplatzer Duct
Occluder [ADO], St. Jude Medical, St. Paul, Minnesota) or
intracardiac defects (Amplatzer muscular VSD occluder
[MVSDO]) using the accompanying delivery system inside
the TAVR sheath. Devices were selected to approach or
exceed the outer diameter of the sheath (8.2 and 9.3 mm for
Edwards 22-F and 24-F sheaths, respectively) and the dis-
tance between the aorta and cava. The occluders were
deployed by exposing the distal disk in the aorta, retracting
to appose the aortic wall, and then deploying the proximal
Figure 2 Crossing Apparatus
(A) A 0.014-inch guidewire is mounted coaxially inside a 0.014- to 0.0135-inch wire convertor, inside a 0.035-inch inner-diameter microcatheter.
(B) The back end of the guidewire is connected to an electrosurgery pencil.
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2797device near or inside the cava. Aortography was performed
immediately before and after device release to assure no
retroperitoneal accumulation of contrast. The device was
recaptured and repositioned if necessary, or replaced after re-
advancing the sheath over a previously placed 0.014-inch
“buddy” guidewire. All patients received protamine to
reverse heparin anticoagulation. The femoral vein access site
was closed using 2 prepositioned sutures (Perclose ProGlide,
Abbott Vascular).
Patients underwent usual post-TAVR care. The ﬁrst 8
patients underwent systematic early CT. With further
experience, this examination was performed before discharge
unless contraindicated, or performed sooner if bleeding was
suspected. In-hospital and 30-day outcomes were ascer-
tained during clinical and imaging examinations. Patients
with patent caval-aortic tracts at time of discharge were
advised to undergo contrast-enhanced CT at 30 days post-
procedure.
Analysis. Data are presented as mean  SD or median
(range). Continuous variables were compared using Stu-
dent’s t-test. Crossing time was recorded as the interval
between the time the caval catheter was ﬁrst directed at the
aorta until the time the introducer sheath was placed in the
aorta, usually including aortic root angiography. Closuretime was the interval between ﬁrst advancement of a nitinol
occluder device until completion aortography. Major
vascular complications and bleeding were classiﬁed accord-
ing to VARC-2 (9), modiﬁed to disregard aorto-caval
ﬁstulas.
Angiographic appearanceof the caval-aortic tract after closure
device placement (Fig. 3) was graded as 0: complete hemostasis
with occluded aorto-caval ﬁstula; 1: patent aorto-caval ﬁstula
without contrast outside the tract; 2: patent aorto-caval ﬁstula
with persistent cruciform-pattern contrast outside the aorto-
caval ﬁstula; and 3: free extravasation outside the aorto-caval
ﬁstula. CT retroperitoneal bleeding after TAVR (Fig. 4) was
graded as 0: absent; 1: blood evident without contrast extrava-
sation; 2: blood evident with contrast extravasation; or 3: blood
evident with organ displacement or with sentinel clot sign.Results
Patients. Nineteen patients with symptomatic severe aortic
valvular heart disease underwent TAVR using caval-aortic
access between July 2013 and January 2014. Baseline de-
mographic characteristics are listed in Table 1. Fifteen pa-
tients were women. Table 2 enumerates contraindications to
conventional TAVR. Two patients had previous aortic root
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2798procedures, including 1 with a stentless bioprosthetic valve.
One had aborted surgical AVR for porcelain aorta, and
another patient had aborted transapical TAVR due to friable
myocardium. Two had unsuccessful previous attempts to
deliver femoral artery introducer sheaths for TAVR. Stan-
dard arterial access was not possible because of peripheral
artery disease (37%) or inadequate iliofemoral artery caliber
for the planned valve. The larger (“best”) iliofemoral artery
minimal diameter was 5.7  1.0 mm.
Procedural outcomes. A representative procedure is shown
in Figure 5 and Online Video 1. Caval-aortic access was
successful in all 19 patients. It required 1.4  0.8 puncture
attempts and a mean of 20 min (range 10 to 75 min) to
perform. Crossings were midway (0.5  0.2) between the
right renal artery and the aortic bifurcation, typically over the
third lumbar vertebral body (0.5 vertebrae). At this posi-
tion, the caval-aortic interluminal distance was 6  3 mm
(range 3 to 12 mm), and the caval and aortic diameters were
21  3 mm and 16  4 mm, respectively. There were no
hemodynamic changes during puncture or sheath placement,
and the sheath was conﬁrmed hemostatic by immediate
abdominal aortography in all patients.
TAVR was successful in 17 patients. One (Patient #6)
required an emergency procedure to retrieve an embolized
transcatheter valve into the left ventricle after low deploy-
ment in an annulus that was too large. Another (Patient
#12) had valve embolization into the aorta due to failure of
rapid pacing during deployment.Figure 3 Typical Angiographic Patterns After Caval-Aortic Transcath
(A) Patent aorto-caval ﬁstula despite closure device (Patient #16). (B) Patent aorto-cava
(C) Contrast extravasation (Patient #14).All patients underwent successful closure device implan-
tation into the caval-aortic tract, including the 1 who un-
derwent an emergency procedure (Table 2). Closure
required 11 min (range 3 to 37 min) and 1.3  0.7 device
deployment attempts. In 5 cases, the device was recaptured
and replaced because of initial malposition or contrast
extravasation before ﬁnal positioning. Five patients (26%)
developed transient hypotension during tract closure,
including 3 patients who required device repositioning;
2 other patients who required repositioning did not have
hypotension. There were 2 other patients who experienced
hypotension during otherwise uncomplicated closure device
placement.
At the conclusion of the procedure, there was residual
aorto-caval ﬂow through the device tract in all patients
(Table 2, Fig. 3). In 12 (63%) patients, there was persistent
extra-aortic contrast during completion of aortography
(cruciform appearance, n ¼ 11; frank extravasation, n ¼ 1).
The device was repositioned in 5 of these patients. Only 4 of
these 12 patients had hypotension.
In-hospital and 30-day outcomes. There was 1 TAVR-
related death during attempted surgical retrieval of an
embolized transcatheter valve (Table 3). All 18 survivors
were either extubated immediately after TAVR (n ¼ 15) or
on the following morning (n ¼ 3).
Vascular complications requiring intervention. Six
patients experienced modiﬁed VARC-2 major vascular
complications, including 2 who were treated witheter Aortic Valve Replacement
l ﬁstula with persistent “cruciform” extra-aortic contrast (Patient #13).
Figure 4 Typical Computed Tomographic Patterns After Caval-Aortic Transcatheter Aortic Valve Replacement
(A) No evident bleeding (Patient #16, day 4). (B) Mild retroperitoneal blood accumulation without contrast extravasation (Patient #4, day 1). (C) Blood present with contrast
extravasation (arrow, Patient #3, day 1). (D) Large retroperitoneal blood accumulation or organ displacement (Patient #9, day 0). In this patient, pararenal hematoma (arrow) is
evident.
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2799percutaneous aortic stent-grafts. Patient #3 had mild
abdominal pain and some peri-aortic blood evident on CT.
Although this patients was hemodynamically stable, she
underwent transfemoral aortic tube stent-graft placement 1
day after TAVR. Patient 14 had cruciform-pattern, extra-
aortic contrast after device repositioning, and had hypoten-
sion that required vasopressors. Six hours afterward, she
underwent aortic stent-graft treatment and no longer
required vasopressors. Patient 9 had a retroperitoneal he-
matoma and transient hypotension that was managed
conservatively. She had hypotension during closure deviceTable 1 Baseline Demographics
Age, yrs 80.7  8.3
Female 15 (79)
BSA, m2 1.79  0.23
Previous cardiac procedure 7 (37)
Peripheral artery disease 7 (37)
eGFR, mL/min/1.73 m2 50.8  21.8
Baseline hemoglobin, g/dl 10.9  1.4
NYHA functional class III or IV heart failure 16 (84)
Atrial ﬁbrillation 10 (53)
STS predicted mortality 7.8  3.8
Euroscore II 7.9  6.2
Moderate to severe mitral regurgitation 7 (37)
Aortic valve area, cm2 0.68  0.16
Values are mean  SD or n (%).
BSA ¼ body surface area; eGFR ¼ estimated glomerular ﬁltration rate; NYHA ¼ New York Heart
Association; STS ¼ Society of Thoracic Surgeons.repositioning, and required 1 U of blood and transient va-
sopressors after the procedure.
Vascular complications not requiring intervention.
Patient 1 had a small retro-aortic pseudoaneurysm detected
on CT that resolved on follow-up CT with conservative
management. Patients 17 and 18 had focal self-contained
aortic dissections in the vicinity of the caval-aortic closure
device. The dissections were partially healed 2 months after
TAVR, as imaged by CT.
Computed tomographic evaluation. When obtained
during hospitalization (n ¼ 16), CT revealed blood in
the retroperitoneal space in 9 patients (56%; mean
retroperitoneal bleeding score 0.9  0.9), which was
graded as mild in 6 patients (Table 2). One patient
(Patient #9 as previously described) had signiﬁcant
retroperitoneal bleeding (Fig. 4).
Bleeding and transfusions. The baseline hemoglobin was
10.9  1.4 g/dl. Fifteen (79%) patients received blood
transfusions overall (mean total 3  4 U), 5 only during
TAVR, 8 only after TAVR, and 2 both during and
after TAVR. These included 2 patients who experienced
major gastrointestinal hemorrhage, 1 who required cardiac
surgery, 2 who required aortic endografts, and 1 (Patient
#9) with retroperitoneal hemorrhage who required over-
night vasopressors. The most serious bleeding was
observed in the 3 patients with elevated international
normalized ratios during TAVR, including the 2 patients
who required endografts and the patient who required
vasopressors (international normalized ratio 2.3  0.3 vs.
Table 2 Caval-Aortic Transcatheter Aortic Valve Replacement Details














1/F Previous SAVR and root repair;
failed previous TA-TAVR;
eGFR<30; STS >10
4.8 22 3 75 12/10-mm ADO d
2/F Frailty; immunocompromised 5.1 24 1 23 10/8 -mm ADO d
3/F Porcelain aorta; failed SAVR;
immunocompromised
6.5 22 3 67 8-mm MVSDO þ
4/F Severe COPD; frailty 6.6 24 3 17 10-mm MVSDO d
5/F Pulmonary artery hypertension;
failed TF-TAVR
7.4 22 3 17 8-mm MVSDO d
6/M Frailty; previous CABG; low EF 4.9 24 2 16 10/8-mm ADO d
7/F Frailty; previous CABG 6.7 22 3 75 6-mm MVSDO d
8/M Severe COPD 4.5 24 1 28 8/6-mm ADO d
9/F Previous aortic root repair; frailty;
failed TF-TAVR; STS >10
5.6 22 2 34 8-mm MVSDO þ
10/F COPD; porcelain aorta 5.0 22 1 14 6-mm MVSDO d
11/M Low EF, previous CABG; eGFR<30;
STS >10
6.0 24 1 14 8-mm MVSDO þ
12/M Frailty, previous CABG 6.1 24 1 10 8-mm MVSDO d
13/F Age >90 yrs; frailty; porcelain aorta;
STS >10
4.0 22 1 24 6-mm MVSDO d
14/F Low EF; previous CABG; STS >10 7.6 24 1 14 8-mm MVSDO þ
15/F Age >90; frailty; COPD; STS >10 5.6 22 1 20 6-mm MVSDO d
16/F COPD, morbid obesity 5.3 24 1 34 10/8-mm ADO þ
17/F Immunocompromised, porcelain
aorta, religious beliefs
5.0 22 1 30 6-mm MVSDO d
18/F Frailty, severe COPD 5.0 24 1 15 8-mm MVSDO d
19/F Age, frailty, previous radiation/
lymph node dissection
6.5 24 1 10 8-mm MVSDO d
Continued on the next page
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28001.4  0.3 without bleeding; p ¼ 0.0002). Overall, these
incidents were classiﬁed as VARC-2 life-threatening bleeding
(16%), major bleeding (32%), minor bleeding (47%), and no
bleeding (5%).
No patient had ischemic or embolic complications related
to caval-aortic access. One had deep vein thrombosis of the
femoral vein used for caval-aortic access, which was treated
with anticoagulation. The patient with valve embolization
into the aorta experienced an ischemic stroke. Two patients
developed contrast-induced nephropathy that required tem-
porary hemodialysis. Nine (50%) patients exhibited mild
transient thrombocytopenia (50 to 100,000 cells/ml). One
patient experienced profound asymptomatic thrombocyto-
penia (<50,000 cells/ml), not attributable to heparin, which
resolved after 6 weeks.
Mean length of stay after TAVR was 8  8 days (range 2
to 37 days).
Follow-up through 111  57 days (range 36 to 229 days)
in the 18 survivors revealed no post-discharge, access-related
adverse events. One patient was readmitted for chest pain
and another was readmitted for diastolic heart failure. Of the
16 patients who underwent repeat imaging (CT, n ¼ 14;
angiography, n ¼ 2) after the ﬁrst week, 15 (94%) exhibited
complete closure of the caval-aortic tract (83% overallclosure rate) by 42  50 days (range 7 to 189 days) after
TAVR. Follow-up imaging was not performed on 2 patients
due to renal insufﬁciency.
Discussion
We described a novel technique enabling TAVR using 8- to
9-mm outer diameter sheaths in patients who were ineligible
to undergo the normal procedure for TAVR. Introducer
sheaths were delivered to the aorta via a tract from the IVC
created by radiofrequency perforation with subsequent
closure using commercial nitinol occluder devices.
Caval-aortic access and tract closure were successful in all
19 patients. One fatality was unrelated to caval-aortic access.
All patients tolerated the technique, but most received blood
transfusion. Most had a residual aorto-caval shunt upon
discharge, which was not hemodynamically signiﬁcant, and
which was occluded in 15 of 18 survivors by 42 days (range
7 to 189 days).
These patients were very ill and were judged to be at
extreme risk, often out of proportion to the Society of
Thoracic Surgeons predicted mortality score of 7.8  3.8%,
as evidenced by the reasons they were ineligible for surgical
























17 d 1 d 1 T, V 15 O, day 44 None
11 d 1 þ 0 d 9 P, day 36 R
48 þ 2 þ 2 T, V 11 O, day 7 None
22 d 2 d 1 d 6 O, day 189 None
7 d 1 d 1 T 8 O, day 42 R
13 þ 1 þ d Death NA NA NA
7 d 1 d 0 T 4 O, day 36 None
8 d 1 d 1 d 2 O, day 86 None
37 þ 2 þ 1 T, V 15 O, day 15 None
8 2 þ 0 MI 8 O, day 8 None
21 d 2 d d d 8 P, day 1 None
18 þ 2 þ 2 S, CIN 34 P, day 1 None
3 d 2 d 0 T 8 O, day 120 None
15 þ 3 d 1 T, V 13 O, day 7 None
3 d 2 þ d d 2 O, day 9 None
12 d 1 d 0 T 5 O, day 56 None
7 d 2 d 0 V 8 O, day 54 None
11 d 2 d 1 T, V, GIB 14 O, day 57 None
4 d 2 d 1 T, GIB, CIN 12 O, day 36 None
Values are n.
ADO ¼ Amplatzer duct occluder; CABG ¼ coronary artery bypass grafting; CIN ¼ contrast-induced nephropathy requiring hemodialysis; COPD ¼ chronic obstructive pulmonary disease; EF ¼ ejection
fraction; GIB ¼ gastrointestinal bleed; MI ¼myocardial infarction; MLD ¼minimal luminal diameter; MVSDO ¼ Amplatzer muscular ventricular septal defect occluder; O ¼ occluded; P ¼ patent; Pt ¼ patient;
R ¼ readmission; RPH ¼ retroperitoneal hemorrhage; S ¼ stroke; SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgeons predicted mortality score; T ¼ transfusion; TA-TAVR ¼
transapical TAVR; TF ¼ transfemoral; V ¼ vascular complication; other abbreviations as in Table 1.
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280117 of 19 patients (89%), compared with 92% in the post-
market Society of Thoracic Surgeons/American College of
Cardiology transcatheter valve therapy registry (10). Vascular
complications were common in this early experience, with
patients having no attractive options. All had heavily calciﬁed
and atherosclerotic aortas; 3 had caval-aortic access into
abdominal aortic aneurysm. Of the 19 patients, 6 (31%) had
vascular complications classiﬁed as VARC-2 major: 3 had
retroperitoneal bleeding, 1 had a small aortic pseudoaneurysm,
and 2 had focal aortic dissections. Two patients with bleeding
were managed with stent-grafts, and the others were managed
conservatively (Fig. 6). From our perspective, endograft ther-
apy and blood transfusion were the signiﬁcant complications.
One-quarter of patients in this series had transient
hypotension during the procedure, which responded to
crystalloid or vasopressors. One of these patients had low
baseline ﬁlling pressures, and the others presumably had
bleeding during (re)positioning of the closure device. Early
in the experience, we obtained immediate post-procedure
CT systematically; later, we obtained immediate CT
only if we suspected active bleeding. Patient 3 underwent
aortic stent grafting although she was hemodynamicallystable, because she had mild abdominal pain and CT
evidence of more-than-mild retroperitoneal blood. In
retrospect, we believe we should have managed this pa-
tient conservatively. However, 2 patients had signiﬁcant
retroperitoneal bleeding, which manifested as persistent
hypotension that required clinical intervention. One of
these 2 patients required low-dose vasopressors for <12 h,
and the other required endograft therapy to achieve he-
modynamic stability.
Retroperitoneal hematoma was expected and common
because our technique used permeable closure devices and
pressurization of the retroperitoneal space with subsequent
venous outﬂow. Unlike other patients with spontaneous,
traumatic, or iatrogenic retroperitoneal arterial hemorrhage,
none of our patients developed abdominal compartment
syndrome or required surgical evacuation. In our series,
baseline hemoglobin was low, and substantial hemoglobin
decline and transfusion were common. Blood loss was
attributed to major gastrointestinal hemorrhage in 2 patients.
We note that in this early experience, patients were volume-
expanded and transfused aggressively because of caution.
Overall, we consider these complications acceptable in light of
Figure 5 Planning and Technique of Caval-Aortic Access
Caval-aortic access for transcatheter aortic valve replacement (TAVR) in Patient 1. (A) Aortography shows severe regurgitation of a bioprosthetic aortic valve causing left
ventricular dilation and intractable heart failure. (B) Simultaneous caval and aortic angiograms. (C) A guidewire is directed from the cava and energized to cross into a pre-
positioned aortic snare. (D) An 8.2-mm diameter sheath is advanced along this guidewire tract from the femoral vein and cava into the aorta. (E) TAVR is performed using a
23-mm balloon-expandable valve. (F) The caval-aortic tract is closed with a nitinol duct occluder (arrow). Completion aortography shows mild residual aorto-caval shunt across
the access tract but no contrast extravasation. (G, H) A contrast-enhanced CT performed 42 days later shows complete occlusion of the tract (Online Video 1).
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2802the paucity of therapeutic options available to these patients.
We expect bleeding risk to be reduced by purpose-built
crossing and closure devices.
The rationale for caval-aortic access is that iliofemoral
veins are larger and more compliant than corresponding
arteries, the IVC is close to the abdominal aorta usually
without interposed structures, and traumatic or aneu-
rysmal aorto-caval ﬁstulas do not necessarily cause im-
mediate hemodynamic compromise (8). We speculate that
a patent caval fenestration allows immediate decompres-
sion of aortic hemorrhage because of the relatively higher
pressure of the retroperitoneal interstitial space. The ret-
roperitoneum behaves as a relatively conﬁned space that
retains insufﬂation gas or saline during laparoscopic pro-
cedure, which is pressurized at 5 to 13 mm Hg after 1 liter
of ﬂuid infusion in cadavers (11,12). In animals, inten-
tional failure to close the aorto-caval ﬁstula was well
tolerated, and free of retroperitoneal bleeding (8). Con-
sistent with these considerations, our ﬁrst patient became
hypotensive when we inadvertently withdrew the sheath
tip just outside the aorta, yet still occluded the cava.
The pressure returned to normal immediately after we
withdrew the sheath farther to allow blood to re-enter
the IVC. Five other patients tolerated 5- to 7-minintervals between removal and replacement of the closure
device when there was an unconstrained aorto-caval
ﬁstula, which is in sharp contrast to the immediate he-
modynamic collapse typically seen shortly after iliac artery
perforation.
We found the overall procedural time related to caval
aortic access and repair to be similar to that typically required
for standard femoral artery access for TAVR, including pre-
placement of vascular sutures, crossover protection, and
balloon inﬂation during vascular hemostasis. In addition,
there appeared to be a “learning curve” of fewer puncture
attempts and shorter crossing and closing times as we
accrued experience (Table 2).
One patient had non-antibody mediated, severe asymp-
tomatic thrombocytopenia (nadir platelet count of 24,000
cells/ml) that resolved at approximately the same time the
caval-aortic tract was found to be closed, and 8 others
experienced >50% decreases in platelet counts without ev-
idence of other hemolysis. Isolated and profound platelet
consumption have been described after device closure of
ductus arteriosus; these were attributed to mechanical
platelet injury. The thrombocytopenia seen in this series may
reﬂect platelet consumption from bleeding or from residual
aorto-caval shunting (13,14).
Table 3 In-Hospital and 30-Day Outcomes
Outcome (n ¼ 19) In-Hospital 30-Day Narrative
Death (from any cause) 1 0 During surgery for embolized
transcatheter valve
Death (access-related) 0 0
Vascular complication:
arterial
6 0 Three had large
retroperitoneal
hematomas, 1 had small
aortic pseudoaneurysm,
and 2 had focal aortic
dissection
Requiring intervention 2 0 Two endografts; 1 for
retroperitoneal bleeding
24 h post-procedure; 1 for
retroperitoneal bleeding




1 0 One deep vein thrombosis at
the access site, treated
with anticoagulation
Requiring intervention 0 0
Stroke 1 0
New-onset claudication 0 0
New-onset CHF 0 0
New-onset GI symptoms 1 0 Nausea
Values are n.
CHF ¼ congestive heart failure; GI ¼ gastrointestinal.
Figure 6 Outcomes of Caval-Aortic Access
Death and major vascular complications are depicted. Abbreviation as Figure 5.
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2803Fifteen of the 19 patients who underwent transcaval
TAVR in this report were women. This likely reﬂects the
smaller diameter of iliofemoral vessels in women. Twelve
(63%) would have had an insufﬁcient iliofemoral artery caliber
(6.0 mm) to allow TAVR using second-generation 16-F to
20-F devices, and 9 (47%) still would have had an insufﬁcient
vessel size (5.5 mm) currently required for third-generation
14-F compatible devices, which are both currently under
investigation in the United States. Our technique may also
enable nonsurgical delivery of other large devices, including
thoracic aortic endografts, percutaneous left ventricular assist
devices, and future larger valves for aortic insufﬁciency.
Study limitations. Limitations to the generalizability of our
report included the small numbers of patients treated at a single
center and the short-term follow-up. However, we expect that
purpose-built access and closure devices should outperform the
commercial devices we used off-label in this experience.
Conclusions
We have demonstrated feasibility of venous access to the
aorta to allow TAVR in otherwise ineligible patients. This
technique challenges conventional wisdom about inten-
tionally violating the wall of the aorta. Caval-aortic access
Greenbaum et al. JACC Vol. 63, No. 25, 2014
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2804may prove useful for TAVR and other large-caliber device
therapy even as future TAVR delivery devices diminish in
size. Further clinical testing is warranted.Acknowledgments
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APPENDIX
For an accompanying video, please see the online version of this article.
